The strategies to reduce iron deficiency in blood donors randomized trial: design, enrolment and early retention
| Autor: | Walter Bialkowski, Rebecca Birch, Joseph E. Kiss, Karen S. Schlumpf, Pamela D'Andrea, Bryan R. Spencer, Alan E. Mast, Barbara J. Bryant, V. Vij, R G Cable, David J. Wright |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Iron Blood Donors Placebo Article law.invention Double-Blind Method Randomized controlled trial law Internal medicine medicine Humans Erythropoiesis Adverse effect Anemia Iron-Deficiency biology business.industry Incidence (epidemiology) Iron Deficiencies Hematology General Medicine Iron deficiency medicine.disease Surgery Ferritin Pill Dietary Supplements biology.protein Female business Iron Dietary |
| Zdroj: | Vox Sanguinis. 108:178-185 |
| ISSN: | 0042-9007 |
| Popis: | Background and Objectives Repeated blood donation produces iron deficiency. Changes in dietary iron intake do not prevent donation-induced iron deficiency. Prolonging the interdonation interval or using oral iron supplements can mitigate donation-induced iron deficiency. The most effective operational methods for reducing iron deficiency in donors are unknown. Materials and Methods ‘Strategies To Reduce Iron Deficiency’ (STRIDE) was a two-year, randomized, placebo-controlled study in blood donors. 692 donors were randomized into one of two educational groups or one of three interventional groups. Donors randomized to educational groups either received letters thanking them for donating, or, suggesting iron supplements or delayed donation if they had low ferritin. Donors randomized to interventional groups either received placebo, 19-mg or 38-mg iron pills. Results Iron deficient erythropoiesis was present in 52·7% of males and 74·6% of females at enrolment. Adverse events within 60 days of enrolment were primarily mild gastrointestinal symptoms (64%). The incidence of de-enrolment within 60 days was more common in the interventional groups than in the educational groups (P = 0·002), but not more common in those receiving iron than placebo (P = 0·68). Conclusion The prevalence of iron deficient erythropoiesis in donors enrolled in the STRIDE study is comparable to previously described cohorts of regular blood donors. De-enrolment within 60 days was higher for donors receiving tablets, although no more common in donors receiving iron than placebo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text